Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDK-703 in advanced solid tumors
NCT05716295Phase 2Terminated
- Sponsor
- Medikine, Inc.
- Start
- Feb 2023
- Primary completion
- Apr 2024
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of MDK-703 in solid tumor, sponsored by Medikine, Inc.. Started Feb 2023; status: terminated.
02
Drugs
MDK-703
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05716295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05716295.